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Abstract
1. FLT3 mutation status does not impact overall survival after allogeneic hematopoietic stem cell 
transplant.
2. Pre-emptive strategies to reduce relapse need to be investigated in FLT3 mutated patients to 
further improve post HCT outcomes.
Background—Patients (pts) with FMS like tyrosine kinase 3 (FLT3) mutated acute myeloid 
leukemia (AML) have poor prognosis and are referred for early allogeneic hematopoietic cell 
transplant (HCT).
Methods—Using data from the Center for International Blood and Marrow Transplant Research 
(CIBMTR), we evaluated 511 adult pts with de novo AML who underwent HCT during 
2008-2011 to determine if FLT3 mutations (mut.) impact HCT outcomes.
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Results—158 (31%) pts had FLT3 mut. Univariate analysis and multivariate analysis showed 
increased relapse risk at 3 years(yr.) in FLT3 mut. group when compared to wild type (WT) group 
(38% (95% confidence intervals [CI] 30-45) vs. 28% (95% CI 24-33), P =0.04; and relative risk 
[RR] 1.60 (95% CI 1.15-2.22), P =0.0048). However, FLT3 mut. status was not significantly 
associated with non-relapse mortality, leukemia-free survival, or overall survival (OS). Though 
more pts in the FLT3 mut. group died from relapsed primary disease (60% vs. 46%) as compared 
to WT, the 3-year OS of pts was comparable 49% (95% CI 40-57) and 55% (95% CI 50-60%) 
P=0.20.
Conclusions—Our data shows that FLT3 mut. status did not adversely impact the OS after HCT 
and about 50% of pts with this mut. who underwent HCT were long term survivors.
Keywords
Acute Myeloid Leukemia; Allogeneic stem cell transplantation; FLT3
INTRODUCTION
HCT remains the most effective post remission therapy for high-risk AML. FLT3 mut. occur 
in about 30% of pts with AML and the 2 most common variants are the internal tandem 
duplications (FLT3-ITD) and the point mut. in the tyrosine kinase domain (FLT3-TKD). 
FLT3-ITD mut. occur more frequently than the TKD mut. (~25% vs. ~7%), and the clinical 
manifestations of a FLT3-ITD mut. have a more characteristically unfavorable risk 
profile.1-9 In contrast with AML with FLT3-TKD, FLT3-ITD mut. is associated with short-
lived remissions, resistant relapsed disease and a dismal prognosis. 2, 3, 10-14 Pts with FLT3-
ITD are therefore commonly offered HCT in CR1. 15-21
Pre-HCT disease characteristics in AML such as disease status (CR1, CR2, MRD) and 
cytogenetics are predictors of post-HCT outcomes.22, 23 The impact of FLT3 mut. on 
outcomes of HCT was previously reported in predominantly normal karyotype AML in CR1 
and was associated with high post-HCT relapses and poor OS (Table 1).20, 24-27 We sought 
to analyze within the CIBMTR database the independent impact of FLT3 mut. on HCT 
outcomes in AML.
PATIENTS AND METHODS
The CIBMTR® is a research collaboration between the NMDP®/Be The Match® and the 
Medical College of Wisconsin. It comprises a group of ≥ 450 transplant centers worldwide 
that contribute detailed data on HCT. Studies conducted by the CIBMTR are performed in 
compliance with all applicable federal regulations pertaining to the protection of human 
research participants. Protected Health Information used in research is collected and 
maintained in CIBMTR's capacity as a Public Health Authority under the HIPAA Privacy 
Rule.
Inclusion Criteria
Adults ≥ 18 yr. with a diagnosis of de novo AML in CR1 or CR2 (M3 was excluded), with 
available FLT3 mut. status who underwent a HLA identical sibling or an 8/8 or 7/8 matched 
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unrelated donor (URD) HCT after myeloablative (MAC), non-myeloablative (NMA), or 
reduced intensity conditioning (RIC) as previously defined28 reported to the CIBMTR from 
2008-2011 were included. Graft source could be either bone marrow or peripheral blood 
stem cells, and any graft-versus-host-disease (GVHD) prophylaxis excluding ex- vivo T cell 
depletion was permitted. Cord blood and haploidentical transplants were excluded to 
decrease heterogeneity and due to small numbers of pts. Centers that never reported FLT3 
mut. were excluded to avoid ascertainment bias. As CIBMTR data collection does not 
distinguish between ITD and TKD mut. or allelic ratios, all pts with FLT3 mut. were 
included.
Endpoints and Statistical Analysis
Patient- and HCT-related characteristics were identified, and the primary endpoints included 
the risk of relapse, non-relapse mortality (NRM), leukemia-free survival (LFS), and OS. 
Cumulative incidence (CI) of relapse was defined as the onset of recurrent AML through 
morphologic evidence in the bone marrow or extra medullary sites, and NRM was 
considered a competing risk. CI of NRM was defined as time to death from any cause while 
in remission, and disease relapse was considered a competing risk. LFS was calculated as 
the interval from HCT to time of relapse or death from any cause. OS was calculated as the 
interval from HCT to death from any cause. Endpoints were calculated at 3 yr.
The Kaplan-Meier estimator was used to calculate the probability of LFS and OS. 
Probabilities of disease relapse, NRM, incidences of acute and chronic GVHD were 
calculated using the CI estimates to account for competing risks. Clinical outcomes 
following HCT for FLT3 mut. and FLT3 WT AML pts were compared adjusting as indicated 
for significant patient-, disease-, and HCT-related variables. Cox proportional hazards 
regression was used to compare the two groups. Backward elimination was used to select 
significant covariates. Proportional hazards assumption was checked. If violated, it was 
added as time-dependent covariate in the Cox model. Interactions between the main effect 
and significant covariates were examined. Due to the strong correlation with FLT3 mut. 
status, WBC count at diagnosis was excluded in multivariate analysis (MVA).
RESULTS
Patient Characteristics
511 pts from 48 reporting centers worldwide between 2008 and 2011 were included in the 
analysis. Median follow-up of survivors was 37 months (12-65). 158 (31%) pts were FLT3 
mut. Patient-, disease- and HCT- characteristics are outlined in Table 2.
Transplant Outcomes
The MVA of outcomes are shown in Table 3.
Relapse Risk
The CI of relapse at 3 yr. was 38% (95% CI 30-45) in the FLT3 mut. group compared to 
28% (95% CI 24-33) in the FLT3 WT group, P=0.04. In MVA, relapse was higher in FLT3 
mut. group (RR 1.6; 95% CI 1.15-2.22, P =0.005) shown in figure 1. Disease status at time 
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of HCT (CR2 vs.CR1, RR 1.52; 95% CI 1.08-2.14, P=0.016) and conditioning intensity 
(RIC/NMA vs. MAC, RR 2.14; 95% CI 1.57-3.70, P<0.001) were associated with increased 
risk of relapse while, HCT from a URD compared to HLA-Identical sibling led to reduced 
relapse risk (RR 0.64; 95% CI 0.45-0.90, P=0.0095). For pts who underwent HCT in CR1, 
relapse was significantly impacted by the number of consolidation cycles, with pts who 
received ≥ 3 consolidations having lower risk of relapse compared to those with no 
consolidation (P= 0.046, 1 cycle [RR 0.76, 95% CI 0.47-1.23], 2 cycles [RR 0.53, 95% CI 
0.28-1.00], and ≥3 cycles [RR 0.45, 95% CI 0.22-0.95]). Pts who underwent HCT in CR2 
with mut. FLT3 also had higher relapse risk (RR 1.83 95% CI 1.00- 1.83, P=0.049) 
compared to pts in CR2 who were FLT3 WT. There was no significant statistical interaction 
between FLT3 status and cytogenetics (P=0.85), FLT3 status and disease status (P=0.18) nor 
cytogenetics and disease status (P=0.99).
GVHD
There was no difference in the incidence of acute GVHD between the FLT3 mut. (38% 
(95%CI 30-45)) and WT groups (32% (95% CI 28-37)) at 100 days (P =0.27). There was no 
difference in chronic GVHD between the FLT3 mut. (61% (95%CI 52-69)) and WT groups 
(60% (95% CI 54-65)) at 3 yr. (P =0.86).
Non-Relapse Mortality
Univariate analysis(UVA) showed no significant difference in the CI of NRM between the 
FLT3 mut.(11% (95% CI 7-17)) and WT groups (13% (95% CI 10-17)) at 1 year (P=0.65). 
In MVA, there was no significant association between FLT3 mut. status and NRM (RR 0.77; 
95% CI 0.48-1.22, P=0.26) (Table 3). Compared to HCT from HLA-identical sibling donors, 
risk of NRM was higher in 7/8 URD (RR 2.82; 95% CI 1.48-5.37, P=0.001). Other adverse 
prognostic factors included the use of total body irradiation based MAC (p=0.047) and HCT 
comorbidity index scores of 1 or greater (P<0.001). In vivo T cell depletion was associated 
with higher NRM within 6 months of HCT (P <0.001).
Leukemia Free Survival
UVA showed no significant difference in the 3 year-LFS between the FLT3 mut. (47%, 95% 
CI 39-55) and WT groups (51%, 95 % CI 45-56) (P=0.42) which was confirmed in MVA 
(RR 1.25; 95% CI 0.96-1.67, P=0.1). LFS was inferior among pts who were transplanted in 
CR2 (RR 1.44; 95% CI 1.09-1.90, P=0.011), among those who underwent RIC/NMA 
preparative regimen (RR 1.52; 95% CI 1.07-2.16, P = 0.021) or had HCT from 7/8 unrelated 
donor (RR 1.58; 95% CI 1.08-2.30, P =0.018). In this model there was no significant 
interaction between FLT3 status and cytogenetics (P= 0.70).
Overall Survival
UVA showed similar OS between the FLT3 mut. (49% (95%CI 40-57)) and WT groups 
(55% (95% CI 50-60)) at 3 yr. (P =0.20). In MVA OS was not significantly associated with 
FLT3 mut. status (RR 1.17; 95% CI 0.89-1.53) as shown in figure 2. OS was inferior among 
pts older than 40 yr. (RR 1.77; 95% CI 1.32-2.37, P < 0.001), and after 7/8 URD (RR 2.33; 
95% CI 1.60-3.40, P < 0.001).
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We re-ran the models for LFS and OS after excluding pts with poor risk cytogenetics and 
there was no significant difference between the two groups (data not shown)
Causes of Death
More pts in the FLT3 mut. group (60% versus 46%) died from their leukemia compared to 
FLT3 WT group (Table 4).
DISCUSSION
Many physicians favor early HCT as the most optimal consolidation18, 19, 29 for pts with 
FLT3 mut. AML though this strategy remains controversial.20, 21, 30-32 In our study, we were 
able to examine the impact of regimen intensity, consolidation, and disease status (CR1 vs. 
CR2) on HCT outcomes in FLT3 mut. AML, with long median follow-up of 37 months. 
This study shows that though pts with FLT3 mut. AML have higher relapse risk after HCT, 
there is no difference in NRM, LFS, or OS, and 49% pts were alive at 3 yr. Furthermore, our 
results show that RIC/NMA conditioning may be a feasible strategy in pts who are 
unsuitable for MAC.
A possible explanation for the increase in relapse risk without concomitant detriment in OS 
may be the differences in post relapse intervention such as early withdrawal of 
immunosuppression; institution of tyrosine kinase inhibitor (TKI) based therapy in FLT3 
mutated pts, or salvage treatment (chemo/donor lymphocyte infusion (DLI), second HCT), 
which are all difficult to capture explicitly in a registry study and may have played a role. 
We reviewed the CIBMTR database to determine if the pts included in this analysis received 
salvage DLI or a 2nd HCT post relapse, and observed that 16 /60 (27%) pts in the FLT3 mut. 
group who relapsed and 39/102 (38%) in the FLT3 WT group who relapsed received a DLI 
or 2nd HCT after relapse.
Brunet et al from the EBMT analyzed outcomes of 206 pts who underwent HLA identical 
sibling and matched URD HCT with only cytogenetically normal FLT3-ITD mut. AML in 
CR1 after MAC. They showed a higher relapse (30% vs. 16%, P=0.0006) but also noted 
inferior LFS (58% vs. 71%, P=0.04) in the FLT3-ITD mut. pts.24
Many pts with FLT3-ITD mut. relapse within 6 months of diagnosis and it is postulated that 
more consolidation in these pts may promote relapse due to upregulation of the FLT3 
ligand.29 In our study, we analyzed the impact of the number of consolidations cycles in pts 
who underwent HCT in CR1 and found that more cycles (≥ 2) of consolidation chemo were 
associated with decreased the risk of relapse. However, it is noted that this data includes only 
pts who survived and received HCT in CR1 and cannot account for those pts who died early 
due to relapse.
Furthermore, our results showed that some pts with FLT3 mut. are able to achieve CR2 and 
undergo HCT. Our study showed that pts with mut. FLT3 in either CR1 or CR2 had similar 
increased relapse risk without adverse effect on NRM, LFS, and OS. While recognizing that 
the cohort of CR2 pts (n=134) is likely to be representative of highly selected pts (those who 
have chemo-sensitive disease that was kinetically stable to allow time for HCT in CR2), our 
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data suggests that pts with FLT3 mut. AML who are able to achieve CR2 should be 
considered for HCT.
Though our study population included FLT3 mut. pts with abnormal cytogenetics, different 
conditioning regimens, and pts in CR1 or CR2, our MVA showed no significant interaction 
among these variables. The limitations of our study include those that are inherent in a 
retrospective registry study. Unfortunately, the data collected by CIBMTR during the study 
period did not include information about type of FLT3 mut. (ITD vs. TKD), allelic ratios, 
and minimal residual status at time of HCT, which precludes comment on these variables.
In summary, we show that HCT may be able to overcome the negative prognostic impact of 
FLT3 mut. in AML with promising LFS and OS. Because most relapses in the FLT3 mut. 
group were early, usually within the first year, continued investigation of pre-emptive 
strategies, such as post -HCT maintenance therapy with FLT3 inhibitors or hypomethylating 
agents, early withdrawal of immunosuppression, and DLI may have value. FLT3 inhibitors 
such as sorafenib33, 34, quizartinib35 and midostaurin are under investigation in the post-
HCT maintenance setting, and may improve outcomes of these high risk pts.
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Table 1
Studies addressing Post HCT outcomes of pts with FLT3 mut.
Reference Total pts FLT3 Mut. underwent 
HCT
Cytogenetics of FLT3 mut. pts Relapse in FLT3 
Mut.pts
OS of FLT3 Mut. pts
20 103 40 Intermediate Increased No Difference
24 206 86 Normal Increased Worse
26 75 16 Normal (12)
Monosomal karyotype (4)
Increased Worse
25 171 50 Intermediate (41)
Unknown (9)
Increased Worse ( p =.334)
27 702 344 Normal Increased Worse

















Variable Wild type Mut. p-value
Number of pts 353 158
Median Age(range) 46 (18-60) 47 (18-60) 0.47
Gender 0.05
    Male 190 (54) 70 (44)
    Female 163 (46) 88 (56)
Recipient race 0.78
    Caucasian 320 (91) 142 (90)
    Non-Caucasian 29 (8) 15 (9)
Karnofsky score 0.92
    <90% 103 (29) 49 (31)
    ≥90% 234 (66) 102 (65)
    Missing 16 (5) 7 (4)
White blood count at diagnosis (×10^9/L) <0.001
Median (range) 10 (<1-344) 34 (<1-305) <0.001
HCT Co-morbidity Index 0.95
    0 131 (37) 57 (36)
    1 91 (26) 40 (25)
    2+ 10 (3) 6 (4)
Missing 121 (34) 55 (35)
Cytogenetic abnormalities <0.001
    Favorable 25 (7) 5 (3)
    Intermediate 216 (61) 128 (81)
                Normal 114 (32) 102(65)
    Poor 101 (29) 20 (13)
    Missing 11 (3) 5 (3)
Disease status prior to HCT 0.07
    CR1 252 (71) 125 (79)
    CR2 101 (29) 33 (21)
Status at CR1 <0.001
    Hematologic CR only 123 (35) 68 (43)
    Cytogenetic and molecular CR 94 (27) 64 (41)
    Cytogenetic CR 130 (37) 22 (14)
    Molecular CR 6 (2) 4 (3)
Time from diagnosis to HCT (for CR1 HCT), months 0.82
Median (range) 4 (2-17) 4 (2-19) 0.59
    <6 months 199 (79) 100 (80)
    ≥6 months 53 (21) 25 (20)
Time to achieve CR1 (for CR1 HCT), weeks 0.05
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FLT3 mut
Variable Wild type Mut. p-value
Median (range) 6 ( 1-71) 5 (1-22) 0.07
Time from CR1 to HCT (for CR1 HCT), weeks 0.12
Median (range) 11 (1-53) 13 (1-76) 0.02
Lines of induction prior to CR1 (for CR1 HCT) 0.06
    1 177 (70) 102 (82)
    2 63 (25) 20 (16)
    ≥3 12 (5) 3 (2)
Type of induction therapy (for CR1 HCT) 0.12
    7+3 156 (62) 72 (58)
    7+3 + other 78 (31) 50 (40)
    Other 16 (6) 3 (2)
Cycle of consolidation therapy prior to CR1 HCT 0.02
    No consolidation given 86 (34) 24 (19)
    1 71 (28) 49 (39)
    2 32 (13) 23 (18)
    ≥3 cycles 33 (13) 17 (14)
    Missing 30 (12) 12 (10)
Duration of CR1 (for CR2 HCT), months 0.006
Median (range) 11 (1-98) 6 (<1-42) 0.006
Time from relapse to HCT (for CR2 HCT), months 0.59
Median (range) 3 ( 1-17) 3 (1-19) 0.76
    0-3 months 41 (41) 14 (42)
    3-6 months 43 (43) 13 (39)
    >6 months 9 (9) 5 (15)
    Missing 8 (8) 1 (3)
Conditioning regimen intensity 0.19
    MAC with TBI 140 (40) 74 (47)
    MAC without TBI 162 (46) 62 (39)
    RIC/NMA 51 (14) 21 (13)
Type of donor 0.69
    HLA-identical sibling 150 (42) 67 (42)
    8/8 URD 165 (47) 70 (44)
    7/8 URD 38 (11) 21 (13)
Donor age of unrelated donor HCT 0.19
Median (range) 30 (19-56) 33 (19-52) 0.04
GVHD prophylaxis 0.75
    Tacrolimus ± others 302 (86) 139 (88)
    CSA ± others 42 (12) 16 (10)
    Others 9 (3) 3 (2)
In vivo T cell Depletion 0.84
    ATG alone 80 (23) 34 (22)
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FLT3 mut
Variable Wild type Mut. p-value
    Alemtuzumab alone 4 (1) 1 (<1)
    No ATG or alemtuzumab 268 (76) 123 (78)
Graft type 0.33
    Bone marrow 59 (17) 21 (13)
    Peripheral blood 294 (83) 137 (87)
Donor/Recipient CMV serostatus 0.60
    R+ 193 (55) 96 (61)
    R-D+ 46 (13) 16 (10)
    R-D− 108 (31) 44 (28)
Donor/Recipient sex match 0.16
    M/M 121 (34) 43 (27)
    M/F 93 (26) 56 (35)
    F/M 69 (20) 27 (17)
    F/F 70 (20) 32 (20)
CSA: cyclosporine; ATG: anti-thymocyte globulin; CMV: cytomegalovirus
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Table 3
MVA of Effect of FLT3 Mut. on Outcomes
N RR (95%CI) p-value








CR2 134 1.52 (1.08-2.14) 0.016
Conditioning intensity
MAC with TBI 214 1 Poverall=0.0003
MAC without TBI 224 1.31 (0.92-1.89) 0.14
RIC/NMA 71 2.41 (1.57-3.70) <.0001
Donor type
HLA-id sibling 217 1 Poverall=0.032
8/8 URD 233 0.64 (0.45-0.90) 0.0095
7/8 URD 59 0.89 (0.53-1.49) 0.65




Yes 157 0.77 (0.48-1.22) 0.26
Other factors:
HCT comorbidity index
0 187 1 Poverall=0.0018
1 131 1.77 (1.06-2.94) 0.028
2+ 16 4.50 (1.99-10.18) 0.0003
Missing 175 1.24 (0.74-2.09) 0.41
Conditioning intensity
MAC with TBI 214 1 Poverall=0.047
MAC without TBI 224 0.58 (0.37-0.90) 0.015
RIC/NMA 71 0.66 (0.35-1.26) 0.21
Donor type
HLA-id sibling 217 1 Poverall=0.0064
8/8 URD 233 1.47 (0.91-2.38) 0.12
7/8 URD 59 2.82 (1.48-5.37) 0.0016
In-vivo T-cell depletion, NRM≤ 6 months
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N RR (95%CI) p-value
No 390 1
Yes 115 3.30 (1.71-6.34) 0.0003
In-vivo T-cell depletion, NRM> 6 months
No 280 1





Yes 157 1.25 (0.96-1.67) 0.099
Cytogenetic abnormalities
Normal 216 1 Poverall=0.026
Favorable 30 0.49 (0.26-0.92) 0.027
Intermediate (excludingnormal) 127 0.94 (0.68-1.29) 0.68
Poor 121 1.21 (0.88-1.68) 0.25
Missing 15 1.69 (0.92-3.13) 0.094
Disease status
CR1 375 1
CR2 134 1.44 (1.09-1.90) 0.011
Conditioning intensity
MAC with TBI 214 1 Poverall=0.028
MAC without TBI 224 0.96 (0.73-1.27) 0.78
RIC/NMA 71 1.52 (1.07-2.16) 0.021
Donor type
HLA-id sibling 217 1 Poverall=0.0081
8/8 or well matched URD 233 0.88 (0.67-1.16) 0.36









40-60 332 1.77 (1.32-2.37) 0.0001
White blood count at diagnosis
<30 299 1 Poverall=0.006
30-100 114 1.43 (1.04-1.95) 0.027
>100 61 1.82 (1.26-2.61) 0.0013
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N RR (95%CI) p-value
Missing 35 1.05 (0.62-1.77) 0.87
Donor type
HLA-id sibling 217 1 Poverall<.0001
8/8 or well matched URD 233 1.17 (0.89-1.55) 0.27
7/8 URD 59 2.33 (1.60-3.40) <.0001
RR: relative risk


















Total deaths 154 77
    Primary disease 71 (46) 46 (60)
    GVHD 21 (14) 8 (10)
    Idiopathic pneumonia syndrome 11 (7) 4 (5)
    Infection 21 (14) 8 (10)
    Organ failure 14 (9) 8 (10)
    Others 14 (9) 2 (3)
    Missing 2 1
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